Aldeyra Therapeutics, Inc. announced enrollment of the first patient into the phase III GUARD trial of ADX 2191 for the prevention of proliferative vitreoretinopathy.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest